XM does not provide services to residents of the United States of America.

EU to set tariffs on Chinese biodiesel in anti-dumping probe



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-EU to set tariffs on Chinese biodiesel in anti-dumping probe</title></head><body>

Adds tariffs for Chinese companies, details on complaint

BRUSSELS, July 19 (Reuters) -The European Union is set to impose provisional duties on Chinese biodiesel after finding it is being sold in EU markets at unfairly low prices, in the latest in a string of trade cases against China.

The European Commission, which oversees EU trade policy, has proposed setting provisional tariffs of between 12.8 and 36.4%, according to a document published on Friday. They are due to be imposed in mid-August.

The investigation is due to continue until February, when definitive duties for five years could be set.

The EU has already set provisional duties for electric vehicles made in China over what it sees as unfair subsidies in its most high-profile case.

For biodiesel, proposed duties are 12.8% for EcoCeres Group products, 36.4% for Jiaao Group, including Zhejiang Jiaao Enproenergy Co 603822.SS, and 25.4% for exports by Zhuoyue Group, including Longyan Zhuoyue New Energy Co 688196.SS

The European Biodiesel Board (EBB), which lodged the complaint, said earlier this month that a flood of biodiesel from China was having a devastating effect on EU production.

Chevron Renewable Energy Group had furloughed German workers, Shell had paused construction of a Dutch plant, BP was pausing a project in Germany and Argent Energy had closed a biorefinery, EBB said.

"While Chinese imports are not the only reason for these decisions, the biodiesel dumping has contributed to the difficulties producers face," it said.

It says Chinese companies exported 1.8 million tonnes of biodiesel to the European Union in 2023, 90% of all Chinese biodiesel exports.

The European Waste-based and Advanced Biofuels Association said it welcomed the measures, adding it believed they would prompt a normalisation of market conditions from an "extremely adverse" situation since late 2022.



Reporting by Philip Blenkinsop and Tassilo Hummel; Editing by Susan Fenton

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.